Q-omics provides the consensus-scored ANKEF1 profile across patient tissues and cancer cell-line models. ANKEF1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANKEF1 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, ANKEF1 protein abundance shows 21,254 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, BLCA, and LUAD as cancer lineages where ANKEF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKEF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKEF1 survival associations across molecular data types. ANKEF1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKEF1 RNA expression–survival associations across cancer types. High ANKEF1 expression shows unfavorable associations in LAML, LGG and GBM, but favorable associations in KIRC, READ and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANKEF1 RNA expression.
This table summarizes ANKEF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ANKEF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKEF1 shows lower tumor expression in THCA and higher tumor expression in BLCA, COAD, HNSC, STAD and KIRP. The BLCA box plot shows higher ANKEF1 RNA expression in tumor versus normal tissue (log2 FC = +1.917, t-test p < 0.001).
This table shows molecular features associated with ANKEF1 in patient tissues and cancer cell lines. In patient samples, ANKEF1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKEF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_SCLC.
